KRAS and cancer: Notably, the PTPN11 (c.1507G>A and c.1508G>T), KRAS (c.35G>A and c.35G>T), and BRAF (c.1797A>G and c.1799T>A) variants are all located in mutational hot spots for cancer and neurodevelopmental disorders.19,20,21 However, except for KRAS c.35G>T and BRAF c.1799T>A, which have been reported in FCDs22,23 and LEATs,24 to our knowledge, none of the other somatic variants have been previously described in focal epilepsies.